Cover Image

Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - the OVAR-IMRT-02 study

The prognosis for patients with advanced FIGO stage III epithelial ovarian cancer remains poor despite the aggressive standard treatment, consisting of maximal cytoreductive surgery and platinum-based chemotherapy. The median time to recurrence is less than 2 years, with a 5-years survival rate of -...

Full description

Saved in:
Bibliographic Details
Main Authors: Rochet, Nathalie (Author) , Kieser, Meinhard (Author) , Sterzing, Florian (Author) , Krause, Sonja (Author) , Lindel, Katja (Author) , Harms, Wolfgang (Author) , Eichbaum, Michael H. R. (Author) , Schneeweiss, Andreas (Author) , Sohn, Christof (Author) , Debus, Jürgen (Author)
Format: Article (Journal)
Language:English
Published: 28 January 2011
In: BMC cancer
Year: 2011, Volume: 11, Pages: 1-7
ISSN:1471-2407
DOI:10.1186/1471-2407-11-41
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-11-41
Get full text
Author Notes:Nathalie Rochet, Meinhard Kieser, Florian Sterzing, Sonja Krause, Katja Lindel, Wolfgang Harms, Michael H. Eichbaum, Andreas Schneeweiss, Christof Sohn, Juergen Debus
Description
Summary:The prognosis for patients with advanced FIGO stage III epithelial ovarian cancer remains poor despite the aggressive standard treatment, consisting of maximal cytoreductive surgery and platinum-based chemotherapy. The median time to recurrence is less than 2 years, with a 5-years survival rate of -20-25%. Recurrences of the disease occur mostly intraperitoneally.
Item Description:Gesehen am 19.09.2022
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-11-41

Similar Items